Skip to main content
. Author manuscript; available in PMC: 2022 Dec 15.
Published in final edited form as: Eur J Med Chem. 2021 Sep 20;226:113849. doi: 10.1016/j.ejmech.2021.113849

Figure 1.

Figure 1.

PROTACs with CDK2 inhibitors (AZD5438 and AT7519-7), linkers and E3 ligase ligands (Pomalidomide and VH-032) used in this study. Pomalidomide and VH-032, have been well studied and by themselves did not show much toxic effects while CRBN based degraders can recruit neo-substrate degradation (e.g. SALL4 for limb deformation) that can cause toxicity [60–67, 74].